Harvard Medical School

Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine for Hair Loss

Retrieved on: 
Tuesday, February 27, 2024

LOS ANGELES , Feb. 27, 2024 /PRNewswire/ -- Pelage Pharmaceuticals, a clinical-stage regenerative medicine company pioneering a new generation of treatments for hair loss, announced today that the company has closed a $16.75 million Series A financing led by GV with participation from Main Street Advisors, Visionary Ventures and YK BioVentures, to advance a first-in-class treatment for androgenetic alopecia or pattern baldness, and other types of alopecia including chemotherapy-induced hair loss.

Key Points: 
  • Additionally, PP405 may also have applications for other types of hair loss such as telogen effluvium (stress-induced hair loss) and chemotherapy-induced hair loss.
  • "What we've observed is that in people who experience hair loss, the actual hair follicle stem cells are still present but have reverted to a dormant state.
  • "Hair loss is an incredibly common health problem with few effective solutions," said Cathy Friedman, Executive Venture Partner, GV and Board Director, Pelage Pharmaceuticals.
  • Pelage is built on rigorous science and offers the opportunity to target the follicle stem cells directly," said Dr. Weng.

American Brain Tumor Association Announces New Board of Directors Officers and Members

Retrieved on: 
Tuesday, February 27, 2024

CHICAGO, Feb. 27, 2024 /PRNewswire/ -- The American Brain Tumor Association announced today the appointment of officers and new members to serve as the Board of Directors.

Key Points: 
  • CHICAGO, Feb. 27, 2024 /PRNewswire/ -- The American Brain Tumor Association announced today the appointment of officers and new members to serve as the Board of Directors.
  • They will advance the ABTA mission under the leadership of Ram Subramanian, Board Chair, and Ralph DeVitto, President and CEO.
  • "Over the past year, the American Brain Tumor Association has experienced tremendous growth, demonstrating the impact of our board's vision and commitment," DeVitto said.
  • The 2024 ABTA Board of Directors Officers and Members:

Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires

Retrieved on: 
Friday, February 16, 2024

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed Richard Baxter to the role of Senior Vice President of Investment Operations, and Karen Reeves, M.D., to Senior Vice President of Clinical Strategy and Investments.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed Richard Baxter to the role of Senior Vice President of Investment Operations, and Karen Reeves, M.D., to Senior Vice President of Clinical Strategy and Investments.
  • “Rich and Karen strengthen our commercial and clinical bench, better positioning us to capitalize on this exciting period in the life sciences industry,” said Todd Davis, CEO of Ligand.
  • “These appointments are the latest in Ligand’s initiative to enhance and scale our deal capabilities by selectively adding new talent.
  • He also served as co-head of the healthcare team at Hayfin Capital Management LLP, which deployed $1.4 billion in capital over four years.

Doxy.me appoints Dr. Esteban López as Chief Medical Officer to drive growth and health equity

Retrieved on: 
Thursday, February 15, 2024

CHARLESTON, S.C., Feb. 15, 2024 /PRNewswire-PRWeb/ -- Doxy.me, a leading telehealth platform, announced the appointment of Esteban López, MD, MBA, as Chief Medical Officer (CMO), effective February 5, 2024. With over 20 years of healthcare leadership experience and a proven track record of utilizing technology to enhance access and quality, Dr. López will spearhead doxy.me's mission to make telemedicine for all and create the future of healthcare.

Key Points: 
  • Doxy.me, the telemedicine platform, has announced its strategic move to bolster growth and advance health equity by appointing a new Chief Medical Officer (CMO).
  • This key hire underlines the company's commitment to enhancing its services and expanding its reach within the healthcare industry.
  • CHARLESTON, S.C., Feb. 15, 2024 /PRNewswire-PRWeb/ -- Doxy.me, a leading telehealth platform, announced the appointment of Esteban López, MD, MBA, as Chief Medical Officer (CMO), effective February 5, 2024.
  • Further emphasizing his commitment to cutting-edge solutions, Dr. López holds a certificate in leading digital transformation in healthcare from Harvard Medical School.

Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments

Retrieved on: 
Thursday, February 15, 2024

According to the American Association for Cancer Research "Cancer immunotherapeutics work by unleashing the power of a patient's immune system to fight cancer and, over the last decade, have emerged as one of the most exciting new approaches to cancer treatment."

Key Points: 
  • According to the American Association for Cancer Research "Cancer immunotherapeutics work by unleashing the power of a patient's immune system to fight cancer and, over the last decade, have emerged as one of the most exciting new approaches to cancer treatment."
  • Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) is developing pelareorep, a unique immunotherapy with the power to awaken the immune system and unlock its antitumor potential.
  • It is committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
  • Bristol-Myers Squibb and Fate Therapeutics are some of the other key patent filers in cancer immunotherapy."

Areteia Therapeutics Announces Appointment of Daniel Becker, M.D., Ph.D. To Board of Directors

Retrieved on: 
Thursday, February 15, 2024

Areteia Therapeutics, Inc. (“Areteia”) today announced the appointment of Daniel Becker to the Areteia Board of Directors, effective immediately.

Key Points: 
  • Areteia Therapeutics, Inc. (“Areteia”) today announced the appointment of Daniel Becker to the Areteia Board of Directors, effective immediately.
  • Dr. Becker will serve as a member of the audit committee of the board.
  • View the full release here: https://www.businesswire.com/news/home/20240215803782/en/
    “I am excited that Dan has been appointed to our board,” said Jorge Bartolome, President and Chief Executive Officer of Areteia.
  • and Ph.D. (Cellular and Molecular Biology) degrees from the University of Michigan and received his B.S.

MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®

Retrieved on: 
Thursday, February 15, 2024

Secondary endpoints include change in fasting plasma glucose after 26 weeks and rate of hypoglycemic events.

Key Points: 
  • Secondary endpoints include change in fasting plasma glucose after 26 weeks and rate of hypoglycemic events.
  • The multi-center study evaluated Afrezza in combination with basal insulin vs. multiple daily injections (MDI) of insulin in children and adolescents aged 4-17 who are living with type 1 or type 2 diabetes.
  • “We are excited to reach this milestone in exploring the potential of Afrezza for a younger generation living with diabetes,” said Dr. Kevin Kaiserman, Senior Vice President, Clinical Development and Medical Affairs for MannKind Corporation.
  • “We expect to complete a primary endpoint analysis in the fourth quarter.”
    More information on the study details is available at: https://www.clinicaltrials.gov/study/NCT04974528

Reproductive Partners Medical Group, an Ivy Fertility Clinic, Expands With New Providers And New Location

Retrieved on: 
Wednesday, February 14, 2024

Dr. Chang and Dr. Brower are both double board certified reproductive endocrinologists and infertility specialists.

Key Points: 
  • Dr. Chang and Dr. Brower are both double board certified reproductive endocrinologists and infertility specialists.
  • “Reproductive Partners Medical Group has stayed at the forefront of our field by honoring our heritage of excellence while continually looking toward the future,” said Lab Medical Director Gayane Ambartsumyan, MD.
  • She received her medical degree from University of California, Davis, and completed her residency in Obstetrics, Gynecology, and Reproductive Medicine at Harvard Medical School.
  • “This is an exciting time to join Reproductive Partners Medical Group and Ivy Fertility,” said Dr. Brower.

Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024

Retrieved on: 
Wednesday, February 14, 2024

MALVERN, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host an in-person Clinical Showcase on Wednesday, February 21, 2024. The event will take place from 10 a.m.-noon ET at the Nasdaq Market Site in Times Square, New York City.

Key Points: 
  • MALVERN, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host an in-person Clinical Showcase on Wednesday, February 21, 2024.
  • The event will take place from 10 a.m.-noon ET at the Nasdaq Market Site in Times Square, New York City.
  • The Clinical Showcase will provide an opportunity to learn more about the upcoming Phase 3 trial of OCU400—including more specifics on study design and the broad indication for the treatment of retinitis pigmentosa, as well as a clinical study update from the ongoing Phase 1/2 trial of OCU400.
  • A panel discussion will offer background on the genesis of modifier gene therapy and how this potential first-in-class treatment approach has evolved from the lab into the clinic.

Star Mountain Capital Adds Former Dallas Fed CEO, Goldman Sachs Vice Chairman, Robert Kaplan, as Senior Advisor

Retrieved on: 
Tuesday, February 13, 2024

Star Mountain Capital , LLC (“Star Mountain”), a rapidly growing specialized private credit and secondaries investment firm targeting systematic alpha and low market correlated returns for its global institutional and high-net-worth investors is pleased to announce that Robert Kaplan has joined as Senior Advisor.

Key Points: 
  • Star Mountain Capital , LLC (“Star Mountain”), a rapidly growing specialized private credit and secondaries investment firm targeting systematic alpha and low market correlated returns for its global institutional and high-net-worth investors is pleased to announce that Robert Kaplan has joined as Senior Advisor.
  • View the full release here: https://www.businesswire.com/news/home/20240213968210/en/
    Robert S. Kaplan, Star Mountain Capital Senior Advisor (Photo: Business Wire)
    Robert Kaplan has over 40 years of investment management, business management, monetary policy, investment banking, and leadership experience.
  • His previous positions include CEO and President of the Federal Reserve Bank of Dallas, Vice Chairman of Investment Banking and Investment Management Divisions of Goldman Sachs, and Professor and Senior Associate Dean of Harvard Business School.
  • “We are honored to have Rob join Star Mountain as an aligned Senior Advisor bringing extensive investment, strategic leadership, business management and governance experience,” said Brett Hickey , Star Mountain Capital Founder & CEO.